Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBG6LP)

Drug Name

SGB-1534 Drug Info

Synonyms

Sgb-1534; 3-{2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl}quinazoline-2,4(1h,3h)-dione hydrochloride(1:1); SGB 1534; AC1Q3ELH; AC1L3TWP; SCHEMBL3624263; CTK8D4853; AKOS030540550; 88068-72-8; 3-(2-(4-(2-Methoxyphenyl)-1-piperazinyl)ethyl)-(1H,3H)-quinazoline-2,4-dione hcl; 3-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-1H-quinazoline-2,4-dione hydrochloride; 2,4(1H,3H)-Quinazolinedione,3-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-, monohydrochloride

Indication

Disease Entry	ICD 11	Status	REF
Hypotension	BA20-BA21	Discontinued in Phase 2	[1]

Cross-matching ID

PubChem CID: 122064
CAS Number: CAS 88068-72-8
TTD Drug ID: DMBG6LP

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Adrenergic receptor alpha-2C (ADRA2C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MOXONIDINE	DMGFB0E	Alcohol dependence	6C40.2	Approved	[3]
Dihydroergocristine	DM5SQ1G	Alcohol dependence	6C40.2	Approved	[4]
Brimonidine	DMQLT4N	Ocular hypertension	9C61.01	Approved	[5]
Amosulalol	DML8QSZ	Hypertension	BA00-BA04	Approved	[6]
Amezinium	DM6I2WQ	Hypotension	BA20-BA21	Approved	[7]
Propylhexedrine	DMTBW2O	Obesity	5B81	Approved	[8]
Tetrahydrozoline	DMT57WC	Ocular disease	1F00.1Z	Approved	[9]
Rilmenidine	DM13PQW	Hypertension	BA00-BA04	Approved	[10]
Xylometazoline	DMKV32D	Allergic rhinitis	CA08.0	Phase 4	[11]
TNX-102	DMO1234	Fibromyalgia	MG30.01	Phase 3	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor alpha-2C (ADRA2C)	TT2NUT5	ADA2C_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000148)
2	Potent alpha-adrenoceptor blocking action of SGB-1534, a new quinazoline antihypertensive agent in vitro experiments. Gen Pharmacol. 1986;17(2):143-9.
3	Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5.
4	Effect of dihydroergocristine on blood pressure and activity at peripheral alpha-adrenoceptors in pithed rats. Eur J Pharmacol. 1984 Jan 13;97(1-2):21-7.
5	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 520).
6	Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5.
7	Pharmacology of amezinium, a novel antihypotensive drug. III. Studies on the mechanism of action. Arzneimittelforschung. 1981;31(9a):1558-65.
8	Airway compromise and delayed death following attempted central vein injection of propylhexedrine. J Emerg Med. 1994 Nov-Dec;12(6):795-7.
9	Prolonged cardiovascular effects after unintentional ingestion of tetrahydrozoline. Clin Toxicol (Phila). 2008 Feb;46(2):171-2.
10	Rilmenidine-induced ocular hypotension: role of imidazoline1 and alpha 2 receptors. Curr Eye Res. 1996 Sep;15(9):943-50.
11	Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39.
12	Clinical pipeline report, company report or official report of Tonix Pharmaceuticals.